Precision Medicine in Oncology® | Specialty

Use of Trabectedin in Soft Tissue Sarcoma

October 21st 2015

Subtyping in Soft Tissue Sarcoma: The PALLETTE Study

October 21st 2015

Chemotherapy Toxicity Considerations in Soft Tissue Sarcoma

October 21st 2015

Chemotherapy Regimens for Advanced Soft Tissue Sarcoma

October 21st 2015

Importance of Surgery and Radiation in Advanced STS

October 21st 2015

Integrating Community Oncologists Into the Multidisciplinary Team

October 21st 2015

Key Members of the Multidisciplinary Team

October 21st 2015

Implementation of Multidisciplinary Sarcoma Care

October 21st 2015

Multidisciplinary Assessment of Soft Tissue Sarcomas

October 21st 2015

Accurately Diagnosing Soft Tissue Sarcoma

October 21st 2015

Incidence and Subtypes of Advanced Soft Tissue Sarcoma

October 21st 2015

Evidence Builds for Multigene Testing for Hereditary Cancers

October 20th 2015

The use of multigene assays to screen patients for hereditary breast and ovarian cancer risk yields clinically valuable information beyond single-gene BRCA testing, but confusion about accurately interpreting the results presents a challenge for clinicians even as panel testing becomes more widely adopted.

Precision Medicine Carries Significant Challenges but Will (Eventually) Lower Cancer Care Costs and Is the Way to Go (Precisely)

October 19th 2015

Our goal should be to use precision medicine as a way to deliver value-based care.

Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

October 16th 2015

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

BRCA+ Patients May Have Higher Risk of Serous Uterine Cancers After RRSO

October 15th 2015

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

TILs Emerge as Robust Biomarker, Shed Light on Immunotherapy Potential in TNBC

October 14th 2015

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Dr. Kapoor on Multigene Panel Testing for Patients at Risk for Breast Cancer

September 26th 2015

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBC

September 26th 2015

Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).

Most Brain Metastases Have Actionable Mutations Not Found in Primary Tumor

September 26th 2015

More than half of brain metastases harbored clinically actionable genetic alterations that were distinct from those associated with the primary tumor.

Deep Sequencing Reveals Possible Primary Resistance Mechanism in EGFR-Mutant NSCLC

September 9th 2015

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.